Log In
Print
BCIQ
Print
Print this Print this
 

Spedra, Stendra, Zepeed, avanafil

Also known as: TA-1790

  Manage Alerts
Collapse Summary General Information
Company Mitsubishi Tanabe Pharma Corp.
DescriptionFast-acting phosphodiesterase-5 (PDE-5) inhibitor
Molecular Target Phosphodiesterase-5 (PDE-5)
Mechanism of ActionPhosphodiesterase-5 (PDE-5) inhibitor
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentMarketed
Standard IndicationErectile dysfunction (ED)
Indication DetailsTreat erectile dysfunction (ED); Treat erectile dysfunction (ED) in patients with Type I and Type II diabetes
Regulatory Designation U.S. - Special Protocol Assessment (Treat erectile dysfunction (ED))
Partner Endo International plc; JW Pharmaceutical Corp.; Menarini Group; Sanofi; Vivus Inc.

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
Total Number of DealsTotal Deal ValueTotal Upfront CashTotal Milestone Payments

3

$361.0M

$35.0M

$429.2M


 Deals Details
DateCompanies InvolvedDeal HeadlineTotal Deal ValueTotal Upfront CashTotal Milestone
Get a free BioCentury trial today